Chang Yuan-Ching, Liu Chien-Liang, Liu Tsang-Pai, Yang Po-Sheng, Chen Ming-Jen, Cheng Shih-Ping
Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan.
Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan.
Pain Pract. 2017 Mar;17(3):336-343. doi: 10.1111/papr.12442. Epub 2016 Feb 23.
Intravenous lidocaine infusion has been shown to reduce postoperative pain among patients undergoing abdominal surgery. This study aimed to evaluate the effects of perioperative lidocaine administration in breast surgery.
A meta-analysis of randomized controlled trials comparing lidocaine infusion vs. placebo/routine treatment was performed. Standardized mean difference (SMD) or risk ratio (RR) with 95% confidence intervals (CIs) was calculated from pooled data. Random-effects models were used, and heterogeneity was assessed.
A total of 4 reports (3 primary studies and 1 extension) with 84 patients randomized to the lidocaine group and 83 patients randomized to the control group were included. There was no difference in pain scores at rest or during activity between the 2 groups from postoperative 2 hours to 3 days. At postoperative 72 hours, the lidocaine group had fewer analgesics consumed (SMD, -0.479; 95% CI, -0.914 to -0.043; P = 0.031). Chronic pain was assessed 3 to 6 months after breast surgery in 51 patients of the lidocaine group and 46 patients of the control group. Patients in the lidocaine group had significantly lower risk for the development of chronic pain (RR, 0.332; 95% CI, 0.141 to 0.781; P = 0.012).
The results indicate no significant benefits of intravenous lidocaine infusion in terms of acute postoperative pain. Although lidocaine seems to attenuate the risk of chronic pain after breast surgery, there is insufficient evidence to conclude that lidocaine infusion is of proved benefit because the results were based on a limited number of small trials.
静脉输注利多卡因已被证明可减轻腹部手术患者的术后疼痛。本研究旨在评估围手术期给予利多卡因在乳腺手术中的效果。
对比较利多卡因输注与安慰剂/常规治疗的随机对照试验进行荟萃分析。从汇总数据中计算标准化均数差(SMD)或风险比(RR)及95%置信区间(CI)。采用随机效应模型,并评估异质性。
共纳入4篇报告(3项主要研究和1项扩展研究),其中84例患者随机分为利多卡因组,83例患者随机分为对照组。术后2小时至3天,两组患者静息或活动时的疼痛评分无差异。术后72小时,利多卡因组的镇痛药消耗量较少(SMD,-0.479;95%CI,-0.914至-0.043;P = 0.031)。在乳腺手术后3至6个月,对利多卡因组的51例患者和对照组的46例患者进行了慢性疼痛评估。利多卡因组患者发生慢性疼痛的风险显著较低(RR,0.332;95%CI,0.141至0.781;P = 0.012)。
结果表明静脉输注利多卡因在急性术后疼痛方面无显著益处。尽管利多卡因似乎可降低乳腺手术后慢性疼痛的风险,但由于结果基于数量有限的小型试验,尚无足够证据得出利多卡因输注有确凿益处的结论。